Skip to main content

Table 1 Baseline patient characteristics in two groups

From: Predictors of contrast-induced acute kidney injury in patients with coronary artery disease receiving contrast agents twice within 30 days

Item

Group A (n = 559)

Group B (n = 48)

P value

Age (year, x ± s)

60.2 ± 11.0

61.5 ± 12.7

0.438

Female [n(%)]

121 (21.6)

14 (29.1)

0.229

Weight (kg, x ± s)

71.7 ± 11.7

72.1 ± 11.7

0.821

Height (cm, x ± s)

169.9 ± 6.6

170.3 ± 6.7

0.699

BMI (kg/m2, x ± s)

24.8 ± 3.6

24.9 ± 3.7

0.930

Current smoker [n(%)]

288 (51.5)

27 (56.2)

0.529

Current alcohol [n(%)]

180 (32.2)

14 (29.1)

0.665

STEMI [n(%)]

196 (35.0)

22 (45.8)

0.136

Hypertension [n(%)]

303 (54.2)

33 (68.7)

0.061

Diabetes [n(%)]

132 (23.6)

16 (33.3)

0.132

CKD [n(%)]

34 (6.1)

6 (12.5)

0.119

Stroke [n(%)]

53 (9.5)

8 (16.7)

0.130

Cancer [n(%)]

4 (0.7)

0

1.000

Peripheral vascular disease [n(%)]

7 (1.3)

2 (4.2)

0.109

Ulcer [n(%)]

58 (10.4)

4 (8.3)

0.807

NYHA class II-III [n(%)]

109 (19.5)

15 (31.3)

0.053

SBP (mmHg, x ± s)

133.9 ± 21.9

136.8 ± 22.4

0.379

DBP (mmHg, x ± s)

79.3 ± 13.4

80.85 ± 13.5

0.426

HR (beat/min, x ± s)

76.4 ± 14.1

81.4 ± 17.3

0.022

Basic-Scr (μmol/L, x ± s)

77.4 ± 25.0

75.1 ± 24.5

0.548

Basic-eGFR [ml/(min•1.73m2), x ± s]

108.4 ± 41.5

110.0 ± 43.0

0.908

BUN (mmol/L, x ± s)

5.9 ± 1.9

6.1 ± 1.3

0.638

K+ (mmol/L, x ± s)

4.1 ± 0.4

4.2 ± 0.3

0.243

Na+ (mmol/L, x ± s)

140.1 ± 3.4

139.6 ± 3.0

0.391

PLT (× 109/L, x ± s)

208.8 ± 55.8

209.5 ± 55.4

0.943

WBC (×109/L, x ± s)

8.3 ± 3.1

8.3 ± 2.8

0.995

Hb (g/L, x ± s)

137.9 ± 24.1

136.2 ± 17.4

0.671

TC (mmol/L, x ± s)

4.2 ± 1.3

4.1 ± 1.0

0.819

TG [mmol/L, M(Q1, Q3)]a

1.48 (1.13,1.72)

1.44 (0.72,1.98)

0.367

ALT [mmol/L, M(Q1, Q3)]a

26.00 (13,81)

24.00 (9,63)

0.975

AST [mmol/L, M(Q1, Q3)]a

25.00 (7,76)

23.00 (4,67)

0.250

ALB (mmol/L, x ± s)

33.2 ± 20.5

35.3 ± 15.5

0.718

HDL-C (mmol/L, x ± s)

1.2 ± 0.4

1.0 ± 0.3

0.684

LDL-C (mmol/L, x ± s)

2.4 ± 1.0

2.4 ± 0.9

0.790

Glucose (mmol/L, x ± s)

6.6 ± 2.9

7.2 ± 3.4

0.337

CK [U/L, M(Q1, Q3)]a

137.00 (27.31,452.50)

108.00 (45.79,168.75)

0.303

CK-MB [U/L, M(Q1, Q3)]a

17.00 (7.14,22.75)

17.00 (6.34,16.75)

0.936

TNT [ng/L, M(Q1, Q3)]a

0.05 (0.01,0.523)

0.05 (0.01,0.162)

0.241

NT-proBNP [μg/L, M(Q1, Q3)]a

83.00 (12.00,1085.00)

140.00 (21.00,2050.00)

0.236

LV (mm, x ± s)

48.8 ± 6.4

49.8 ± 5.8

0.687

EF (%, x ± s)

58.9 ± 10.7

57.6 ± 11.6

0.730

Medicine care [n(%)]

 Diuretics

210 (37.6)

27 (56.3)

0.011

 CCB

231 (41.3)

21 (43.8)

0.743

 β-RB

469 (83.9)

40 (83.3)

0.918

 ACEI/ARB

444 (79.4)

34 (70.8)

0.162

 Statins

366 (65.5)

37 (77.1)

0.102

 Digitalis

103 (18.4)

17 (35.4)

0.005

  1. Group A No CI-AKI from second agent, Group B CI-AKI from second agent, BMI Body mass index, STEMI ST-segment elevation myocardial infarction, CKD Chronic kidney disease, NYHA New York Heart Association, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, Scr Serum creatinine, eGFR Estimated glomerular filtration rate, BUN Blood urea nitrogen, PLT Platelets, WBC White blood cells, Hb Hemoglobin, TC Total cholesterol, TG Triglycerides, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALB Albumin, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, CK Creatine kinase, CK-MB Creatine kinase-myocardial band, TNT Troponin T, NT-proBNP N-terminal pro-brain natriuretic peptide, LV Left ventricular, EF Ejection fraction, CCB Calcium channel blocker, β-RB β-receptor blocker, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin II receptor antagonist
  2. aMeans nonnormally distributed continuous variables
Back to article page

Military Medical Research

ISSN: 2054-9369